Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,215.00 at Royal Bank of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price decreased by Royal Bank of Canada from $1,260.00 to $1,215.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target suggests a potential upside of 44.03% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. TD Cowen raised their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $1,090.24.

Regeneron Pharmaceuticals Trading Up 0.6 %

Shares of REGN opened at $843.60 on Friday. Regeneron Pharmaceuticals has a twelve month low of $783.57 and a twelve month high of $1,211.20. The stock has a market cap of $93.00 billion, a PE ratio of 20.88, a P/E/G ratio of 2.88 and a beta of 0.15. The company has a quick ratio of 4.62, a current ratio of 5.99 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $1,058.43 and its 200-day moving average price is $1,039.88.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the prior year, the firm posted $8.79 EPS. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 37.46 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. SteelPeak Wealth LLC raised its stake in Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 692 shares in the last quarter. Atria Investments Inc raised its position in shares of Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after acquiring an additional 941 shares in the last quarter. Tri Locum Partners LP raised its position in shares of Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after acquiring an additional 8,949 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Regeneron Pharmaceuticals by 23.2% in the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after purchasing an additional 5,495 shares during the period. Finally, Tidal Investments LLC boosted its position in shares of Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after purchasing an additional 711 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.